AKBA
$2.52
Akebia Therapeutics
($.15)
(5.62%)
AKBA
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.33)
Revenue:  $52.58 Mil
Thursday
Feb 3
8:05 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AKBA reports earnings?
Beat
Meet
Miss

Where is AKBA's stock price going from here?
Up
Flat
Down
Stock chart of AKBA
Analysts
Summary of analysts' recommendations for AKBA
Score
Grade
Pivots
Resistance
$2.83
$2.77
$2.64

$2.58

Support
$2.45
$2.39
$2.26
Tweet
Growth
Description
Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalMerck & Co.ZoetisEli LillyBristol-Myers SquibbPfizerInterCept